The dominant cultural image of cannabis use involves getting high — altered perception, euphoria, impaired cognition. But a growing body of research and clinical experience suggests that the most therapeutically useful doses of cannabis may be far lower than recreational doses — low enough to produce no perceptible intoxication at all. This is the principle behind microdosing.
Microdosing cannabis means using doses small enough to produce therapeutic effects without noticeable psychoactive effects. For THC, this typically means 1–5mg per dose — compared to the 10–30mg doses common in recreational use. The goal is to find the minimum effective dose: enough to reduce pain, anxiety, or other symptoms without impairing function.
The concept draws on a well-established pharmacological principle: dose-response relationships for cannabinoids are often biphasic — meaning low doses and high doses can produce opposite effects. Low-dose THC may reduce anxiety; high-dose THC can cause anxiety and paranoia. Low-dose THC may improve focus; high-dose THC impairs cognition. This biphasic pattern makes microdosing particularly relevant for conditions where high-dose cannabis is counterproductive.
A landmark 2012 study by Portenoy et al. in the Journal of Pain and Symptom Management examined three doses of nabiximols (THC/CBD spray) in cancer pain patients: low (1–4 sprays/day), medium (6–10 sprays/day), and high (11–16 sprays/day). The low-dose group showed the greatest pain reduction — significantly better than both medium and high doses. The high-dose group actually showed worse outcomes than placebo. This inverted U-shaped dose-response curve has been replicated in multiple subsequent studies.
A 2020 study by Aviram and Samuelly-Leichtag found that patients who used lower cannabis doses reported better quality of life outcomes than those using higher doses, despite similar symptom severity at baseline. The researchers proposed that lower doses maintain receptor sensitivity while avoiding tolerance and adverse effects.
People who have never used cannabis or haven't used it in years have high CB1 receptor sensitivity. Starting with 1–2.5mg THC is appropriate — standard recreational doses can cause overwhelming anxiety and dysphoria in cannabis-naive individuals.
THC has a biphasic effect on anxiety — low doses are anxiolytic, high doses are anxiogenic. Microdosing (1–5mg THC) combined with CBD is the optimal approach for anxiety. Higher doses frequently worsen anxiety and can trigger panic attacks.
Patients who need to maintain cognitive function, drive, or operate machinery during the day. Microdosing allows symptom management without functional impairment — though even 2.5mg THC can affect some individuals' driving ability.
Older adults are more sensitive to THC's psychoactive and cardiovascular effects. Starting with 1–2.5mg THC is essential. Falls risk from dizziness and orthostatic hypotension is a real concern at standard doses in elderly patients.
Low-dose cannabis combined with opioids may provide additive analgesia, allowing opioid dose reduction. The goal is not to replace opioids suddenly but to gradually reduce them as cannabis provides supplemental pain relief.
The "start low, go slow" principle is the foundation of all cannabis microdosing protocols. Here's a structured approach:
Once daily, evening only. Assess tolerance and response. Note any psychoactive effects, anxiety, or side effects.
Once or twice daily if well-tolerated. Add morning dose only if no impairment from evening dose.
If adequate symptom relief achieved, maintain current dose. If insufficient, increase by 1–2.5mg increments. If side effects, reduce dose.
Identify the lowest dose providing adequate symptom relief. This is your maintenance microdose. Reassess monthly.
Microdosing represents a paradigm shift in how we think about cannabis therapeutics — away from "more is better" and toward precision dosing. For many patients, particularly those new to cannabis, those with anxiety, or those who need to maintain daily function, microdosing may provide the best therapeutic window: meaningful symptom relief without the cognitive and psychoactive effects that make higher doses impractical. The evidence base is still developing, but the pharmacological rationale is sound and clinical experience is increasingly supportive.